Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin.
Pretargeted tumour imaging was performed in nude mice bearing subcutaneous LS174T human colon cancer xenografts with streptavidin-CC49 monoclonal antibody and 111In-DTPA-biocytin. Mice were administered 250 micrograms of streptavidin-CC49, followed 6 or 9 days later by 40 ng (250 microCi) of 111In-DTPA-biocytin. Tumors were visualized at 24 h postinjection of 111In-DTPA-biocytin. Tumour uptake was 0.9-2.5% injected dose/g with tumour/nontarget ratios from 2:1 to 37:1 (except for kidney, which was 0.5-3:1). Tumour uptake in mice pretargeted with streptavidin or streptavidin-conjugated nonspecific normal mouse IgG was < 0.1% i.d./g.
Alvarez-Diez
T M
TM
Division of Nuclear Medicine, Toronto Hospital, Ontario, Canada.
Polihronis
J
J
Reilly
R M
RM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism; D001426:Bacterial Proteins / Q000493:pharmacokinetics; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D005260:Female; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D008239:Lysine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D019809:Streptavidin; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D001426:Bacterial Proteins; D006023:Glycoproteins; D018796:Immunoconjugates; D007205:Indium Radioisotopes; C102681:alpha,omega-(bis)DTPA-biocytin; C047052:tumor-associated antigen 72; D004369:Pentetic Acid; D019809:Streptavidin; D008239:Lysine